Drug intelligence / Profile preview

HSN003839

Development stage: Preclinical
Lead developer: Beijing Pharscin Innobio
Modality: Small Molecules
Administration: Oral

Overview

HSN003839 is a first-in-class **small molecule** inhibitor of **ubiquitin-specific protease 21** being developed by **Chongqing Joywin** for **cancer** treatment. The program is attributed to Joywin's subsidiary Huasen Inno and is positioned as an **anti-tumor targeted therapy** in **preclinical development**. Available preclinical descriptions indicate that HSN003839 is a highly potent and selective USP21 inhibitor with low-nanomolar enzymatic activity, inhibition of cancer cell proliferation, favorable mouse oral exposure, and antitumor activity in a CDX mouse model without significant body-weight loss.

Targets

USP21 (Ubiquitin-specific protease 21)

Beyond the preview

Go deeper on HSN003839.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSN003839.

Explore the full profile